• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?

作者信息

Boziou Maria, Dionyssiou Dimitrios, Dionyssopoulos Dimitrios, Lazaridou Elizabeth, Lallas Aimilios, Apalla Zoe

机构信息

Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Department of Plastic Surgery, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

出版信息

Dermatol Pract Concept. 2023 Jul 1;13(3):e2023160. doi: 10.5826/dpc.1303a160.

DOI:10.5826/dpc.1303a160
PMID:37557110
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10412069/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/968c/10412069/7877c1542f4c/dp1303a160g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/968c/10412069/7877c1542f4c/dp1303a160g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/968c/10412069/7877c1542f4c/dp1303a160g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/968c/10412069/7877c1542f4c/dp1303a160g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/968c/10412069/7877c1542f4c/dp1303a160g001.jpg

相似文献

1
Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?西米普利单抗能否成为色素性干皮病的改变命运之药？
Dermatol Pract Concept. 2023 Jul 1;13(3):e2023160. doi: 10.5826/dpc.1303a160.
2
Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review.着色性干皮病的免疫治疗：1例用西米普利单抗治疗的晚期皮肤鳞状细胞癌病例及文献综述
Oncotarget. 2021 May 25;12(11):1116-1121. doi: 10.18632/oncotarget.27966.
3
Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review.附录：着色性干皮病的免疫治疗：1例使用西米普利单抗治疗的晚期皮肤鳞状细胞癌病例及文献综述
Oncotarget. 2022 Aug 4;13:985. doi: 10.18632/oncotarget.28265.
4
Clinical, cellular, and molecular features of an Israeli xeroderma pigmentosum family with a frameshift mutation in the XPC gene: sun protection prolongs life.一个XPC基因发生移码突变的以色列着色性干皮病家族的临床、细胞和分子特征：防晒可延长寿命。
J Invest Dermatol. 2000 Dec;115(6):974-80. doi: 10.1046/j.1523-1747.2000.00190.x.
5
Xeroderma pigmentosum: an updated review.着色性干皮病：最新综述
Drugs Context. 2022 Apr 25;11. doi: 10.7573/dic.2022-2-5. eCollection 2022.
6
Recurrent squamous cell carcinoma and a novel mutation in a patient with xeroderma pigmentosum: a case report.色素性干皮病患者复发性鳞状细胞癌及新突变：病例报告。
J Med Case Rep. 2022 Jul 28;16(1):306. doi: 10.1186/s13256-022-03524-2.
7
[Xeroderma pigmentosum].[着色性干皮病]
Presse Med. 1997 Dec 20;26(40):1992-7.
8
Xeroderma pigmentosum.着色性干皮病
Eur J Dermatol. 2003 Jan-Feb;13(1):4-9.
9
Life-threatening vocal cord paralysis in a patient with group A xeroderma pigmentosum.一名患有A型着色性干皮病的患者出现危及生命的声带麻痹。
Pediatr Neurol. 2004 Mar;30(3):222-4. doi: 10.1016/j.pediatrneurol.2003.09.009.
10
Xeroderma pigmentosum and acute myeloid leukemia: a case report.着色性干皮病并急性髓系白血病：一例报告。
J Med Case Rep. 2021 Aug 26;15(1):437. doi: 10.1186/s13256-021-02969-1.

引用本文的文献

1
Immune checkpoint inhibitors for children with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma: A case presentation and brief review.用于患有色素沉着干皮病和晚期皮肤鳞状细胞癌儿童的免疫检查点抑制剂：病例报告及简要综述
J Dtsch Dermatol Ges. 2025 Mar;23(3):303-308. doi: 10.1111/ddg.15648. Epub 2025 Jan 26.

本文引用的文献

1
Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review.着色性干皮病的免疫治疗：1例用西米普利单抗治疗的晚期皮肤鳞状细胞癌病例及文献综述
Oncotarget. 2021 May 25;12(11):1116-1121. doi: 10.18632/oncotarget.27966.
2
Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma.一名患有着色性干皮病和晚期鳞状细胞癌的患者对帕博利珠单抗的反应。
JCO Precis Oncol. 2019 Sep 20;3. doi: 10.1200/PO.19.00028. eCollection 2019.
3
Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
一名患有着色性干皮病的患者转移性皮肤血管肉瘤对免疫检查点抑制剂产生显著反应：全基因组测序辅助终末期疾病的治疗决策
Cold Spring Harb Mol Case Stud. 2019 Oct 23;5(5). doi: 10.1101/mcs.a004408. Print 2019 Oct.
4
Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.着色性干皮病中皮肤鳞状细胞癌预防的免疫治疗策略。
Br J Dermatol. 2019 Nov;181(5):1095-1097. doi: 10.1111/bjd.18144. Epub 2019 Aug 7.
5
Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.着色性干皮病患者的抗程序性细胞死亡-1 免疫疗法对皮肤癌和黑色素瘤转移的疗效。
Br J Dermatol. 2018 May;178(5):1199-1203. doi: 10.1111/bjd.16270. Epub 2018 Feb 26.
6
Dramatic response to nivolumab in xeroderma pigmentosum skin tumor.色素性干皮病皮肤肿瘤对纳武单抗有显著反应。
Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26837. Epub 2017 Oct 8.
7
Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.一名着色性干皮病患者的转移性皮肤鳞状细胞癌对派姆单抗的快速反应：病例报告及文献复习
Eur J Cancer. 2017 Sep;83:99-102. doi: 10.1016/j.ejca.2017.06.022. Epub 2017 Jul 19.
8
Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.帕博利珠单抗（PD1抗体）使着色性干皮病中的黑色素瘤转移灶及多种非黑色素瘤皮肤癌消退。
Eur J Cancer. 2017 May;77:84-87. doi: 10.1016/j.ejca.2017.02.026. Epub 2017 Mar 31.